Study of the relationship between miRNA level in blood plasma of ovarian cancer patients and chemotherapy sensitivity to cis-platin
10.3760/cma.j.issn.1008-1372.2014.07.022
- VernacularTitle:卵巢癌患者血浆 miRNA 水平与顺铂化疗敏感性的相关性研究
- Author:
Zhaoxia FENG
;
Yuliang HUANG
;
Xianhui OUYANG
- Publication Type:Journal Article
- Keywords:
Ovarian neoplasms/drug therapy;
MicroRNAs/blood;
Cisplatin/therapeutic use;
Prognosis
- From:
Journal of Chinese Physician
2014;(7):930-933
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the potentiality of specific miRNA level in blood plasma of ovarian cancer patients as a molecular marker to predict sensitivity and response to platinum-based chemotherapy .Methods Quantitative polymerase chain reac-tion ( Q-PCR) was used to check the changing of miRNA level in blood plasma before and after chemotherapy , and explored the rela-tivity between variation and chemotherapy response and clinic outcome .Results Among preliminary screened 11 miRNAs, only 5 miRNAs were able to be detected in peripheral blood .There existed variations in 3 miRNAs ( miR-22, miR-106a, miR-142).Further detection of the changing of miRNA level in blood plasma before and after therapy , miR-22 was found significantly up-regulated in blood plasma that was underwent platinum-based chemotherapy .Meanwhile, ovarian cancer patients with high miR-22 level were most-ly sensitive to platinum-based therapy.Otherwise, miR-22 was positive relative to the clinic prognosis of patients with ovarian cancer . Conclusions miR-22, miR-106a, and miR-142 might participate in the generation and development of ovarian cancer .miR-22 in pe-ripheral blood was probably identified as a novel molecular marker of prediction of the sensitivity to platinum in ovarian cancer patients .
